They next showed that combined treatment with thapsigargin, a general SERCA inhibitor, and 2-deoxy-d-glucose (2-DG, acting as an NF-kB inhibitor) reduces the tumor burden, while 2-DG alone, that mimics glucose starvation, had a lower effect in a breast cancer xenograft model [83]. The gene discussed is NFKB1; the disease is breast carcinoma.